Company · VRTX
Vertex Pharmaceuticals
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
10
9 still marketed
Novel approvals
7
Approvals since 2021
15
Originals and new uses
Phase 3 trials
87
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Trikafta (Copackaged) new use Priority reviewOrphanMar 27, 2026
- Trikafta (Copackaged) new use Priority reviewOrphanMar 27, 2026
- Alyftrek new use Priority reviewOrphanMar 27, 2026
- Kalydeco new use Priority reviewOrphanMay 22, 2025
- Kalydeco new use Priority reviewOrphanMay 22, 2025
- Journavx approved NovelBreakthrough therapyPriority reviewJan 30, 2025
- Trikafta (Copackaged) new use Priority reviewOrphanDec 20, 2024
- Trikafta (Copackaged) new use Priority reviewOrphanDec 20, 2024
- Alyftrek approved NovelPriority reviewOrphanDec 20, 2024
- Orkambi new use Priority reviewOrphanDec 13, 2024
Drugs in development (13)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- PovetaciceptALPN-303Phase 37 trials
Vertex Pharmaceuticals · Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy
- VX-121D-IVA, CTP-656Phase 33 trials
Vertex Pharmaceuticals · Cystic Fibrosis
- matched to PregabalinPhase 32 trials
Vertex Pharmaceuticals · Diabetic Peripheral Neuropathic Pain
- matched to SUZPhase 32 trials
Vertex Pharmaceuticals · Diabetic Peripheral Neuropathic Pain
- VX-147Inaxaplin, IXPPhase 32 trials
Vertex Pharmaceuticals · Proteinuric Kidney Disease
- ZimislecelFormerly known as STx-02, VX-880Phase 32 trials
Vertex Pharmaceuticals · Type 1 Diabetes, Kidney Transplant, Diabetes Mellitus, Type 1
- Exa-celPhase 31 trial
Vertex Pharmaceuticals · Sickle Cell Disease, Hematological Diseases, Hemoglobinopathies
- VX-017Phase 31 trial
Vertex Pharmaceuticals · Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
- matched to VX-993Phase 22 trials
Vertex Pharmaceuticals · Diabetic Peripheral Neuropathic Pain, Acute Pain
- VX-670Phase 22 trials
Vertex Pharmaceuticals · Myotonic Dystrophy Type 1 (DM1)
- VX-993Phase 22 trials
Vertex Pharmaceuticals · Diabetic Peripheral Neuropathic Pain, Acute Pain
- VX-264Phase 21 trial
Vertex Pharmaceuticals · Type 1 Diabetes
- VX-407Phase 21 trial
Vertex Pharmaceuticals · Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Recruiting Phase 3 trials
Largest first.
- Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral NeuropathyPivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06628908 · 1,100 participants (planned) · Start Oct 1, 2024 · Primary completion May 31, 2027
Drug: Suzetrigine; Placebo (matched to SUZ) and 2 more · For: Diabetic Peripheral Neuropathic Pain
Sites: Anniston, Alabama; Birmingham, Alabama; Daphne, Alabama · 76 sites in all
- Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral NeuropathyPivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07231419 · 734 participants (planned) · Start Nov 21, 2025 · Primary completion Apr 6, 2027
Drug: Suzetrigine; Placebo (matched to SUZ) · For: Diabetic Peripheral Neuropathic Pain
Sites: Birmingham, Alabama; Mobile, Alabama; Glendale, Arizona · 75 sites in all
- Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)Pivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07204275 · 176 participants (planned) · Start Sep 30, 2025 · Primary completion Jun 27, 2029
Drug: Povetacicept; Tacrolimus · For: Primary Membranous Nephropathy
Sites: Montgomery, Alabama; Surprise, Arizona; Los Angeles, California · 119 sites in all
- A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 DiabetesPivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT04786262 · 57 participants (planned) · Start Mar 29, 2021 · Primary completion Dec 31, 2027
Drug: VX-880; VX-017 · For: Diabetes Mellitus, Type 1; Impaired Hypoglycemic Awareness; Severe Hypoglycemia
Sites: Duarte, California; San Francisco, California; Miami, Florida · 29 sites in all
- A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled SyringePivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07890909 · 40 participants (planned) · Start Nov 13, 2026 · Primary completion Dec 12, 2027
Drug: Povetacicept; Sibeprenlimab · For: Immunoglobulin A Nephropathy
Sites: Orlando, Florida; Lawrenceville, Georgia
- Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell DiseasePivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05477563 · 26 participants (planned) · Start Aug 2, 2022 · Primary completion Jun 9, 2027
Drug: CTX001 · For: Beta-Thalassemia; Thalassemia; Hematologic Diseases and 4 more
Sites: New York, New York; Charlotte, North Carolina; Nashville, Tennessee · 6 sites in all
- An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney TransplantPivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06832410 · 10 participants (planned) · Start Mar 31, 2025 · Primary completion Sep 17, 2026
Drug: Biological/Vaccine · For: Type 1 Diabetes; Kidney Transplant
Sites: Philadelphia, Pennsylvania; Pittsburgh, Pennsylvania; Madison, Wisconsin · 7 sites in all
Marketed drugs (9)
Newest FDA action first.
- Trikafta (Copackaged) Elexacaftor, Ivacaftor, Tezacaftor, Ivacaftor · 2023
- Trikafta (Copackaged) Elexacaftor, Ivacaftor, Tezacaftor, Ivacaftor · 2019
- Alyftrek Deutivacaftor, Tezacaftor, Vanzacaftor Calcium · 2024
- Kalydeco Ivacaftor · 2015
- Kalydeco Ivacaftor · 2012
- Orkambi Ivacaftor, Lumacaftor · 2018
- Orkambi Ivacaftor, Lumacaftor · 2015
- Symdeko (Copackaged) Ivacaftor, Ivacaftor, Tezacaftor · 2018
- Journavx Suzetrigine · 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.